Gossamer Bio, Inc.

    Jurisdiction
    United States
    LEI
    549300ZOC0N2W6PSFR58
    ISIN
    US38341P1021 (GOSS)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    trending_flat 50 / 100
    Even with peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    2 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    2 / 7

    Profile

    Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €34.67M
    Gross margin
    100.0%
    EBIT
    -€125.46M
    EBIT margin
    -361.9%
    Net income
    -€119.53M
    Net margin
    -344.8%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €37.14M +7.1% -€125.42M +4.9%
    €106.76M +187.5% -€56.35M -55.1%
    €218.40M +104.6% €37.74M -167.0%

    Dividends

    No dividend payouts

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Milligan Sandra N/A +26K $1.92 +$50.02K

    Earnings Calls

    Latest earnings call: March 3, 2022

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 1.6M $1.73M -143K Sell

    Add to watchlist

    Notifications